title: Ribosomal protein S6 is highly expressed in non-Hodgkin lymphoma and associates with mRNA containing a 5' terminal oligopyrimidine tract.
abstract: The molecular mechanism(s) linking tumorigenesis and morphological alterations in the nucleolus are presently coming into focus. The nucleolus is the cellular organelle in which the formation of ribosomal subunits occurs. Ribosomal biogenesis occurs through the transcription of ribosomal RNA (rRNA), rRNA processing and production of ribosomal proteins. An error in any of these processes may lead to deregulated cellular translation, evident in multiple cancers and 'ribosomopathies'. Deregulated protein synthesis may be achieved through the overexpression of ribosomal proteins as seen in primary leukemic blasts with elevated levels of ribosomal proteins S11 and S14. In this study, we demonstrate that ribosomal protein S6 (RPS6) is highly expressed in primary diffuse large B-cell lymphoma (DLBCL) samples. Genetic modulation of RPS6 protein levels with specifically targeted short hairpin RNA (shRNA) lentiviruses led to a decrease in the actively proliferating population of cells compared with control shRNA. Low-dose rapamycin treatments have been shown to affect the translation of 5' terminal oligopyrimidine (5' TOP) tract mRNA, which encodes the translational machinery, implicating RPS6 in 5' TOP translation. Recently, it was shown that disruption of 40S ribosomal biogenesis through specific small inhibitory RNA knockdown of RPS6 defined RPS6 as a critical regulator of 5' TOP translation. For the first time, we show that RPS6 associates with multiple mRNAs containing a 5' TOP tract. These findings expand our understanding of the mechanism(s) involved in ribosomal biogenesis and deregulated protein synthesis in DLBCL.
authors.affiliation: Marlene and Stewart Greenebaum Cancer Center, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201,USA.
authors.forename: P R
authors.initials: PR
authors.lastname: Hagner
authors.forename: K
authors.initials: K
authors.lastname: Mazan-Mamczarz
authors.forename: B
authors.initials: B
authors.lastname: Dai
authors.forename: E M
authors.initials: EM
authors.lastname: Balzer
authors.forename: S
authors.initials: S
authors.lastname: Corl
authors.forename: S S
authors.initials: SS
authors.lastname: Martin
authors.forename: X F
authors.initials: XF
authors.lastname: Zhao
authors.forename: R B
authors.initials: RB
authors.lastname: Gartenhaus
mesh_terms: D045744:Cell Line, Tumor; D002466:Cell Nucleolus / Q000502:physiology; D004722:Endoribonucleases / Q000032:analysis; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000378:metabolism*; D010641:Phenotype; D039102:Poly(A)-Binding Proteins / Q000032:analysis; D014176:Protein Biosynthesis; D038641:RNA 5' Terminal Oligopyrimidine Sequence / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics; D038601:Ribosomal Protein S6 / Q000032:analysis / Q000502:physiology*; D012270:Ribosomes / Q000502:physiology; D020123:Sirolimus / Q000494:pharmacology; D000074019:T-Cell Intracellular Antigen-1
chemical_list: D039102:Poly(A)-Binding Proteins; D012333:RNA, Messenger; D038601:Ribosomal Protein S6; D000074019:T-Cell Intracellular Antigen-1; C071558:TIA1 protein, human; D004722:Endoribonucleases; C467723:DCP2 protein, human; D020123:Sirolimus